Feasibility Assessment of a Medical Device for Tumour Cell Retention and Radiotherapy Sensitization in Patients With Suspected High-grade Glioma

Overview

This is a prospective, multicenter, single-arm, pilot clinical investigation, aimed at evaluating the safety and preliminary efficacy of the GlioHook implant in patients with high-grade glioma undergoing surgical resection followed by standard of care (SoC) treatment. GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins, decreasing infiltration and focalizing the disease, while improving the effects of radiotherapy. Once implanted, GlioHook exerts a dual mechanism that combines tumour cell focalization and radiosensitization.

Detailed description

This clinical investigation is designed to evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal, in patients with high-grade glioma undergoing surgical resection followed by standard of care. Preliminary efficacy of the medical device such as Progression-Free Survival (PFS) will also be assessed.

Interventions

• Device GlioHook device
  GlioHook is a sterile medical device designed to be implanted after tumour resection surgery in suspected high grade glioma patients, covering the entire surface of the tumour resection margins.

Primary outcome measures

• To evaluate the safety of the GlioHook implant, as measured by the occurrence of adverse events related to the GlioHook implant, as well as events involving the need for device removal [Time frame: 24 months]

Secondary outcome measures (7)

• To evaluate the preliminary efficacy of GlioHook, measured as Progression-Free Survival (PFS), defined according to RANO 2.0 criteria. [Time frame: 24 months]
• 6 months Progression-Free Survival (PFS) [Time frame: 6 months]
• Adjuvant Progression-Free Survival (PFS) [Time frame: 24 months.]
• To evaluate the preliminary efficacy of GlioHook, measured as Overall Survival (OS). [Time frame: 24 months]
• To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)) [Time frame: 6 months]
• To evaluate changes in quality of life during the follow-up period (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Brain Cancer Module (EORTC QLQ-BN20)) [Time frame: 6 months]
• To evaluate changes in neurological function during the follow-up period (Neurologic Assessment in Neuro-Oncology (NANO scale)) [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

• Willing and able to provide written informed consent prior to the performance of any study-specific procedures.
• Age ≥18 and <70 years at the time of consent.
• Suspected newly diagnosed unifocal high-grade glioma, as suggested by preoperative MRI imaging.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Supratentorial and/or lobar tumor mass with a volume of less than 60cm3 as assessed by preoperative MRI.
• Patient scheduled to undergo surgical resection of the target brain lesion, with an expected extent of resection (EOR) ≥90% based on preoperative imaging and surgical planning and according to the investigator's criteria. The anticipated EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI.
• Candidate to receive standard-of-care treatment for newly diagnosed glioblastoma, according to current clinical practice and the investigator's judgment.
• Able to undergo contrast-enhanced MRI.
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and study procedures and accessible for follow-up after completion of study treatment.
• For women of childbearing potential (WOCBP):

• Must have a negative serum or urine pregnancy test within 7 days prior to inclusion.
• Must not be pregnant or breastfeeding at the time of inclusion.
• Must agree to use a highly effective method of contraception during the entire study participation period and for at least 6 months after the last dose of temozolomide.
• Male and female patients of reproductive potential must agree to use highly effective contraceptive methods.

Exclusion criteria

• Life expectancy <3 months, as estimated by the investigator.
• Surgical resection cannot be assured or is considered not feasible or unsafe based on preoperative assessment.
• Tumor located in the posterior fossa or involving critical subcortical structures (e.g., midbrain, brainstem, ventricles, or basal ganglia), where safe surgical resection cannot be achieved.
• Presence of multifocal, bilateral, or recurrent tumor, or prior diagnosis of glioblastoma or other intracranial malignancy.
• Extent of tumor resection <90%. The EOR should be verified intraoperatively using a validated available method depending on availability at study site, such as 5-aminolevulinic acid (5-ALA) fluorescence guidance, ultrasound, or MRI. However, it is up to the neurosurgeon to assess, after reviewing the available data and the resection itself, whether the patient meets the criteria for implantation.
• Significant active or uncontrolled concurrent medical conditions, including but not limited to:

• Active infection requiring systemic therapy,
• Symptomatic congestive heart failure,
• Unstable angina pectoris,
• Clinically significant cardiac arrhythmia,
• Uncontrolled hypertension,
• Severe pulmonary, hepatic, or renal disease,
• Psychiatric or social conditions that, in the opinion of the investigator, would interfere with study compliance or follow-up.
• Severe blood clotting disorders
• Known hypersensitivity to bovine-derived collagen or other components of the medical device.
• Contraindication to contrast-enhanced MRI, including known allergy to gadolinium or presence of non-MRI-compatible implants.
• Contraindication to receive radiotherapy or temozolomide, including prior cranial irradiation exceeding safe cumulative dose limits.
• Participation in another interventional clinical trial or use of an investigational product within 30 days prior to inclusion, or planned participation during this clinical investigation.
• Women who are pregnant or breastfeeding.
• Men or women of reproductive potential unwilling to use adequate contraception, as defined in the inclusion criteria.
• Inability or unwillingness to comply with clinical investigation procedures, follow-up schedule, or CIP requirements, as judged by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Other

Study locations

Spain · 3 centers

• Hospital Universitario Vall d'Hebron — Barcelona
• Hospital HM Sanchinarro — Madrid
• Complejo Hospitalario Universitario de Santiago — Santiago de Compostela

Identifiers

NCT: NCT07725640 · CT-GlioHook-2026-01

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗